TW200718678A - Methods of preparing MEK inhibitor - Google Patents

Methods of preparing MEK inhibitor

Info

Publication number
TW200718678A
TW200718678A TW095121036A TW95121036A TW200718678A TW 200718678 A TW200718678 A TW 200718678A TW 095121036 A TW095121036 A TW 095121036A TW 95121036 A TW95121036 A TW 95121036A TW 200718678 A TW200718678 A TW 200718678A
Authority
TW
Taiwan
Prior art keywords
methods
mek inhibitor
preparing
preparing mek
phenylamino
Prior art date
Application number
TW095121036A
Other languages
Chinese (zh)
Inventor
Erwin Ayandra Irdam
Thomas Norman Nanninga
Edward Mark Davis
Howard Isaac Tjiong
Justin Kaine Weaver
Derick Dale Winkle
Original Assignee
Warner Lambert Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Warner Lambert Co filed Critical Warner Lambert Co
Publication of TW200718678A publication Critical patent/TW200718678A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C259/00—Compounds containing carboxyl groups, an oxygen atom of a carboxyl group being replaced by a nitrogen atom, this nitrogen atom being further bound to an oxygen atom and not being part of nitro or nitroso groups
    • C07C259/04—Compounds containing carboxyl groups, an oxygen atom of a carboxyl group being replaced by a nitrogen atom, this nitrogen atom being further bound to an oxygen atom and not being part of nitro or nitroso groups without replacement of the other oxygen atom of the carboxyl group, e.g. hydroxamic acids
    • C07C259/10—Compounds containing carboxyl groups, an oxygen atom of a carboxyl group being replaced by a nitrogen atom, this nitrogen atom being further bound to an oxygen atom and not being part of nitro or nitroso groups without replacement of the other oxygen atom of the carboxyl group, e.g. hydroxamic acids having carbon atoms of hydroxamic groups bound to carbon atoms of six-membered aromatic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

This invention relates to methods of preparing MEK inhibitor N-[(R)-2,3-dihydroxy-propoxy]-3,4- difluoro-2-(2-fluoro-4-iodo-phenylamino)-benzamide that useful for treating diseases mediated by MEK activity in mammals. The present invention provides new synthetic routes that are safe, efficient and cost effective when carried out on a commercial scale.
TW095121036A 2005-06-14 2006-06-13 Methods of preparing MEK inhibitor TW200718678A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US69062005P 2005-06-14 2005-06-14

Publications (1)

Publication Number Publication Date
TW200718678A true TW200718678A (en) 2007-05-16

Family

ID=36952557

Family Applications (1)

Application Number Title Priority Date Filing Date
TW095121036A TW200718678A (en) 2005-06-14 2006-06-13 Methods of preparing MEK inhibitor

Country Status (4)

Country Link
JP (1) JP2006348034A (en)
AR (1) AR057362A1 (en)
TW (1) TW200718678A (en)
WO (1) WO2006134469A1 (en)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012019113A2 (en) * 2010-08-05 2012-02-09 Case Western Reserve University Inhibitors of erk for developmental disorders of neuronal connectivity
CN103204822B (en) 2012-01-17 2014-12-03 上海科州药物研发有限公司 Benzoxazole compounds as protein kinase inhibitors, and preparation method and application thereof
MX2023009555A (en) 2021-02-17 2023-11-10 Warner Lambert Co Compositions of essentially pure form iv of n-((r)-2,3- dihydroxypropoxy)-3,4-difluoro-2- (2-fluoro-4-iodophenylamino)- benzamide and uses thereof.
CN117083264A (en) 2021-02-17 2023-11-17 斯普林渥克斯治疗股份有限公司 Crystalline solids of the MEK inhibitor N- ((R) -2, 3-dihydroxypropoxy) -3, 4-difluoro-2- (2-fluoro-4-iodo-phenylamino) -benzamide and uses thereof
US11084780B1 (en) 2021-02-17 2021-08-10 Springworks Therapeutics, Inc. Crystalline solids of MEK inhibitor N-((R)-2,3-dihydroxypropoxy)-3,4-difluoro-2-(2-fluoro-4-iodo-phenylamino)-benzamide and uses thereof
US11571402B2 (en) 2021-02-17 2023-02-07 Springworks Therapeutics, Inc. Dispersible formulations of N-((R)-2,3-dihydroxypropoly)-3,4-difluoro-2-(2-fluoro-4-iodo-phenylamino)-benzamide and uses thereof
US11066358B1 (en) 2021-02-17 2021-07-20 Warner-Lambert Company Llc Compositions of essentially pure form IV of N-((R)-2,3-dihydroxypropoxy)-3,4-difluoro-2-(2-fluoro-4-iodo-phenylamino)-benzamide and uses thereof

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4965270A (en) * 1987-05-30 1990-10-23 Beecham Group P.L.C. Purine derivatives
HU230251B1 (en) * 2000-07-19 2015-11-30 Warner-Lambert Co. Ester derivatives of 4-iodo phenylamino benzhydroxamic acids and pharmaceutical compositions containing them
EP1682495A1 (en) * 2003-10-21 2006-07-26 Warner-Lambert Company LLC Polymorphic form of n- (r)-2,3-dihydroxy-propoxy -3,4-d ifluoro-2-(2-fluoro-4-iodophenylamino)-benzamide

Also Published As

Publication number Publication date
WO2006134469A1 (en) 2006-12-21
JP2006348034A (en) 2006-12-28
AR057362A1 (en) 2007-11-28

Similar Documents

Publication Publication Date Title
TW200718678A (en) Methods of preparing MEK inhibitor
TW200633693A (en) Use of MEK inhibitors in treating abnormal cell growth
TW200621684A (en) Methods for the manufacture of biphenyl amines
RS51151B (en) N-sulphonylpyrroles and their use as histone deacetylase inhibitors
EA200700717A1 (en) СУЛЬФОНАМИНЫ
BRPI0413124A (en) method and equipment to improve performance
ME00039B (en) Phenyl-piperazine derivatives as serotonin reuptake inhibitors
BR0109188A (en) Substituted 5-Amide Diarylamines as Mex Inhibitors
WO2003103603A3 (en) Novel formate salt of o-desmethyl-venlafaxine
MX2013013346A (en) Competitive price alert system with competitive price rules engine.
TW200505829A (en) Protease inhibitors for coronaviruses and sars-cov and the use thereof
TW200744567A (en) Phenylethylamine analogs and their use for treating glaucoma
ATE510822T1 (en) POTASSIUM CHANNEL INHIBITORS
ATE460359T1 (en) AEROSOL
GR1005865B (en) NEW SIGMA LIGANDS with anti-apoptotic and/or pro-apoptotic action on the cells biochemical mechanisms and neuroprotective, anti-cancer, anti-metastatic, and anti-chronic inflammatory properties.
MX2010000956A (en) Compounds which inhibit beta-secretase activity and methods of use thereof.
BR0314247A (en) Condensed Palatinose In Hydrogenated Form
TW200710075A (en) Process for preparing at least one target product by partial oxidation and/or ammoxidation of propylene
MA33120B1 (en) METHOD OR SYSTEM USING BIOMARKERS FOR MONITORING TREATMENT
EP1476423A4 (en) Arylsulfonamidobenzylic compounds
NO20061705L (en) Use of agomelatine for the manufacture of drugs intended for the treatment of bipolar disorders
FR2890079B1 (en) DETECTION OF SALMONELLA LACTOSE +
TW200712873A (en) Profiling systems and methods
ECSP055715A (en) USE OF PYRIMETHANIL IN RESISTANT PATHOGENS
UY29778A1 (en) NEW ASSOCIATION BETWEEN AGOMELATIN AND A NORADRENALINE RECOVERY INHIBITOR AND PHARMACEUTICAL COMPOSITIONS CONTAINING IT.